Is Lotiglipron legal in the United Kingdom?

It worked. 901 participants, HbA1c down 1.44 percent, weight down 7.47 percent against 1.84 on placebo, and the trial was stopped early for safety.

Lotiglipron is the clearest illustration of why an oral GLP-1 pill was harder than it looked, because the problem was never whether it worked. Pfizer ran a phase 2 dose-ranging study in 901 participants across two cohorts, type 2 diabetes and obesity.

Mechanism: A small-molecule agonist at the GLP-1 receptor, taken orally. Unlike semaglutide, which is a peptide requiring an absorption enhancer to survive the gut in tablet form, a small molecule can be absorbed conventionally, which is the entire commercial appeal.

Regulatory history: Never approved. The phase 2 programme was terminated early for safety and development did not continue.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Lotiglipron at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.